FGF23 and chronic kidney disease: The modulation of FGF23 may improve patient outcomes, as an iFGF23 reduction of 30% in patients with CKD using a calcimimetic during the EVOLVE trial was associated with reducing both adverse vascular outcomes and all‐cause mortality (Moe et al., 2015).